Grants and Contracts Details
Description
Our long-term goal is to develop new treatment options for SAH patients. The overall objective of this preclinical application is to evaluate the effectiveness of CBD as a therapy for vasospasm. CBD not only possesses anti-inflammatory properties, but evidence indicates it also relaxes and stabilizes the vasculature. Taken together, we hypothesize that CBD therapy will reduce SAH-induced inflammation and CV, thereby improving survival rates and limiting cognitive impairment.
| Status | Finished |
|---|---|
| Effective start/end date | 2/1/21 → 1/31/22 |
Funding
- University of Kentucky Neuroscience Research Priority Area: $25,000.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.